tislelizumab + cetuximab + irinotecan

This is a combination regimen of three drugs—tislelizumab (a humanized IgG4 anti-PD-1 monoclonal antibody), cetuximab (a chimeric IgG1 anti-EGFR monoclonal antibody), and irinotecan (a topoisomerase I inhibitor small molecule chemotherapeutic). The combination is being investigated for the treatment of refractory or recurrent RAS wild-type metastatic colorectal cancer that has failed at least two prior lines of therapy. Tislelizumab blocks the PD-1/PD-L1 immune checkpoint pathway to enhance antitumor immunity. Cetuximab inhibits EGFR signaling to block tumor cell proliferation and may also promote immune-mediated cytotoxicity. Irinotecan inhibits DNA replication by targeting topoisomerase I. Preclinical and clinical studies suggest that combining EGFR inhibition with chemotherapy can sensitize tumors to immunotherapy in microsatellite stable colorectal cancer[1][2][7].

Other names

Tislelizumab Combined With Cetuximab and IrinotecanTislelizumab Plus Cetuximab and IrinotecanThird-line regimens-Shanghai Zhongshan Hospital-colorectal cancer